Liverpool set to lead new £1.5M cystic fibrosis trial


The University of Liverpool and Alder Hey Children’s Hospital have been awarded £1.5 million from the National Institute for Health Research to conduct a trial to improve the lives of people with cystic fibrosis (CF).

The CF STORM trial aims to address how the treatment burden for people with CF could be safely reduced, which has been identified as a top research priority by patients and their healthcare teams.

People with CF spend many hours every day on multiple treatments, including aerosolised therapies delivered by nebulisers to keep their lungs stable and prevent chest infections. The recent UK introduction of the highly effective triple therapy drug Kaftrio, which is suitable for many people with CF, provides an ideal opportunity to robustly explore reduction in treatment burden in a clinical trial.

CF STORM will enrol people with CF across the UK who have been established on Kaftrio and take a daily nebulised muco-active therapy, with the aim of evaluating whether their daily treatment regime can be rationalised without a significant reduction in their respiratory function.

The Chief Investigators are Professor Kevin Southern from the University of Liverpool (pictured above) and Dr Gwyneth Davies from University College London, and the trial will be run by the Liverpool Clinical Trials Centre.

The CF STORM team has worked closely with the Cystic Fibrosis Trust and other partners to involve people with CF and their families in the research design and process. The current challenges of the COVID-19 pandemic have also been taken into consideration and trial participants will require no extra hospital visits.

Professor Kevin Southern, from the Department of Women’s and Children’s Health, said: “As transformative therapies emerge for CF and other conditions it is important that we evaluate rigorously the impact on the patient journey.

“To secure funding for non-COVID research during this time is a challenge, especially in such a rapid manner, and the CF STORM team would like to thank both the Liverpool Health Partners SPARK office and the R&D team at Alder Hey Children’s Hospital for their timely and enthusiastic support.”

For more information about the trial, please contact

[callout title=Related News]Benefits of ‘transformational’ cystic fibrosis drug highlighted in new review.[/callout]